NASDAQ: NTHINeonc Technologies Holdings Inc Stock
$5.61-0.79 (-12.34%)
Updated Jun 13, 2025
NTHI Price
$5.61
Fair Value Price
-$0.18
Market Cap
$106.74M
52 Week Low
$4.11
52 Week High
$25.00
P/E
N/A
P/B
-11.09x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.88
Operating Cash Flow
N/A
Beta
-1.66
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NTHI Overview
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NTHI's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
NTHI
Ranked#133 of 464
Ranked#133 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.18 | A | |
| $41.59 | A | |
| $23.53 | A |
Be the first to know about important NTHI news, forecast changes, insider trades & much more!
NTHI News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NTHI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NTHI ($5.61) is overvalued by 3,156.35% relative to our estimate of its Fair Value price of -$0.18 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NTHI ($5.61) is not significantly undervalued (3,156.35%) relative to our estimate of its Fair Value price of -$0.18 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NTHI's short-term liabilities ($18.07M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
There are 30 more NTHI due diligence checks available for Premium users.
Valuation
NTHI fair value
Fair Value of NTHI stock based on Discounted Cash Flow (DCF)
Price
$5.61
Fair Value
-$0.18
Undervalued by
3,156.35%
NTHI ($5.61) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NTHI ($5.61) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NTHI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-11.09x
Industry
4.66x
NTHI's financial health
Profit margin
Revenue
$40.0k
Net Income
-$38.0M
Profit Margin
-95,028.7%
Assets to liabilities
Assets
$8.4M
Liabilities
$18.1M
Debt to equity
-1.88
NTHI's short-term liabilities ($18.07M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NTHI's short-term assets ($7.36M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NTHI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NTHI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.7M
Investing
$0.0
Financing
$11.0M
NTHI vs Biotech Stocks
Neonc Technologies Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.